Dna (recombinant Vaccinia Virus Strain Livp Clone Gl-onc1) Uses, Dosage, Side Effects and more
Dna (recombinant Vaccinia Virus Strain Livp Clone Gl-onc1) is under investigation in clinical trial NCT01443260 (A Study of GL-ONC1, an Oncolytic Vaccinia Virus, in Patients With Advanced Peritoneal Carcinomatosis).
| Trade Name | Dna (recombinant Vaccinia Virus Strain Livp Clone Gl-onc1) |
| Generic | Olvimulogene nanivacirepvec |
| Olvimulogene nanivacirepvec Other Names | Dna (recombinant vaccinia virus strain livp clone gl-onc1), DNA (synthetic vaccinia virus oncolytic-strain GLV-1h68 (complete genome)), Olvimulogene nanivacirepvec |
| Type | |
| Groups | Investigational |
| Therapeutic Class | |
| Manufacturer | |
| Available Country | |
| Last Updated: | January 7, 2025 at 1:49 am |
